219 related articles for article (PubMed ID: 12040355)
1. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy.
Tumlin JA; Wang A; Murray PT; Mathur VS
Am Heart J; 2002 May; 143(5):894-903. PubMed ID: 12040355
[TBL] [Abstract][Full Text] [Related]
2. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
Stone GW; McCullough PA; Tumlin JA; Lepor NE; Madyoon H; Murray P; Wang A; Chu AA; Schaer GL; Stevens M; Wilensky RL; O'Neill WW;
JAMA; 2003 Nov; 290(17):2284-91. PubMed ID: 14600187
[TBL] [Abstract][Full Text] [Related]
3. Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.
Stone GW; Tumlin JA; Madyoon H; Lepor NE; McCullough PA; Mathur VS; Murray PT; O'Neill WW
Rev Cardiovasc Med; 2001; 2 Suppl 1():S31-6. PubMed ID: 12439366
[TBL] [Abstract][Full Text] [Related]
4. Preventing contrast-induced nephropathy with fenoldopam.
Hunter DW; Chamsuddin A; Bjarnason H; Kowalik K
Tech Vasc Interv Radiol; 2001 Mar; 4(1):53-6. PubMed ID: 11981789
[TBL] [Abstract][Full Text] [Related]
5. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial.
Tumlin JA; Finkel KW; Murray PT; Samuels J; Cotsonis G; Shaw AD
Am J Kidney Dis; 2005 Jul; 46(1):26-34. PubMed ID: 15983954
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial.
Morelli A; Ricci Z; Bellomo R; Ronco C; Rocco M; Conti G; De Gaetano A; Picchini U; Orecchioni A; Portieri M; Coluzzi F; Porzi P; Serio P; Bruno A; Pietropaoli P
Crit Care Med; 2005 Nov; 33(11):2451-6. PubMed ID: 16276165
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy.
Kurnik BR; Allgren RL; Genter FC; Solomon RJ; Bates ER; Weisberg LS
Am J Kidney Dis; 1998 Apr; 31(4):674-80. PubMed ID: 9531185
[TBL] [Abstract][Full Text] [Related]
8. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention.
Kini AA; Sharma SK
Rev Cardiovasc Med; 2001; 2 Suppl 1():S19-25. PubMed ID: 12439364
[TBL] [Abstract][Full Text] [Related]
9. Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial.
Bove T; Zangrillo A; Guarracino F; Alvaro G; Persi B; Maglioni E; Galdieri N; Comis M; Caramelli F; Pasero DC; Pala G; Renzini M; Conte M; Paternoster G; Martinez B; Pinelli F; Frontini M; Zucchetti MC; Pappalardo F; Amantea B; Camata A; Pisano A; Verdecchia C; Dal Checco E; Cariello C; Faita L; Baldassarri R; Scandroglio AM; Saleh O; Lembo R; Calabrò MG; Bellomo R; Landoni G
JAMA; 2014 Dec; 312(21):2244-53. PubMed ID: 25265449
[TBL] [Abstract][Full Text] [Related]
10. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam.
Kini AS; Mitre CA; Kim M; Kamran M; Reich D; Sharma SK
Catheter Cardiovasc Interv; 2002 Feb; 55(2):169-73. PubMed ID: 11835641
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
[TBL] [Abstract][Full Text] [Related]
12. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients.
Madyoon H; Croushore L; Weaver D; Mathur V
Catheter Cardiovasc Interv; 2001 Jul; 53(3):341-5. PubMed ID: 11458411
[TBL] [Abstract][Full Text] [Related]
13. Effects of prophylactic fenoldopam infusion on renal blood flow and renal tubular function during acute hypovolemia in anesthetized dogs.
Halpenny M; Markos F; Snow HM; Duggan PF; Gaffney E; O'Connell DP; Shorten GD
Crit Care Med; 2001 Apr; 29(4):855-60. PubMed ID: 11373482
[TBL] [Abstract][Full Text] [Related]
14. Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy.
Chamsuddin AA; Kowalik KJ; Bjarnason H; Dietz CA; Rosenberg MS; Gomes MD; McDermott CM; Hunter DW
AJR Am J Roentgenol; 2002 Sep; 179(3):591-6. PubMed ID: 12185025
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure.
Frank H; Werner D; Lorusso V; Klinghammer L; Daniel WG; Kunzendorf U; Ludwig J
Clin Nephrol; 2003 Sep; 60(3):176-82. PubMed ID: 14524580
[TBL] [Abstract][Full Text] [Related]
16. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients.
Brienza N; Malcangi V; Dalfino L; Trerotoli P; Guagliardi C; Bortone D; Faconda G; Ribezzi M; Ancona G; Bruno F; Fiore T
Crit Care Med; 2006 Mar; 34(3):707-14. PubMed ID: 16505657
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients.
Madyoon H
Rev Cardiovasc Med; 2001; 2 Suppl 1():S26-30. PubMed ID: 12439365
[TBL] [Abstract][Full Text] [Related]
18. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
Briguori C; Colombo A; Airoldi F; Violante A; Castelli A; Balestrieri P; Paolo Elia P; Golia B; Lepore S; Riviezzo G; Scarpato P; Librera M; Focaccio A; Ricciardelli B
J Am Coll Cardiol; 2004 Aug; 44(4):762-5. PubMed ID: 15312855
[TBL] [Abstract][Full Text] [Related]
19. Contrast-induced nephropathy: protective role of fenoldopam.
Caixeta A; Dogan O; Weisz G
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):497-505. PubMed ID: 22642656
[TBL] [Abstract][Full Text] [Related]
20. Fenoldopam and renal function after partial nephrectomy in a solitary kidney: a randomized, blinded trial.
O'Hara JF; Mahboobi R; Novak SM; Bonilla AM; Mascha EJ; Fergany AF; Campbell SC; Kaouk JH; Kaple KM; Gill IS; Ziegman SA; Sessler DI
Urology; 2013 Feb; 81(2):340-5. PubMed ID: 23374797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
